X-Chem

October 15, 2020

Clinical setback lays bare Vertex’s weakness

As the company is punished for its failure to diversify, could it be forced into making an acquisition?

June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data

Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

April 26, 2019

Astra’s first attempt fails, but there’s no giving up on KRAS

After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.

X-Chem

Clinical setback lays bare Vertex’s weakness

Asco 2019 – KRAS chase heats up with Amgen data

Astra’s first attempt fails, but there’s no giving up on KRAS

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Finding the next Vertex

Clinical setback lays bare Vertex’s weakness

SITC 2020 – embargo snafu triggers the first movers

Biopharma buyouts still pricey

More biotechs test the third way to market